



Clinical Research Advances in Endometrial Carcinoma

Guest Editor:

Dr. Salvatore Lopez

Ginecologia Oncologica, IRCCS
Istituto Tumori "Giovanni Paolo
II", Bari, Italy

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editor

Endometrial cancer (EC) is the most common gynecologic malignancy in industrialized nations, and its incidence is increasing globally. Although EC is diagnosed at an early stage, about 20% of early-stage EC patients present poor outcomes. Furthermore, although the overall survival (OS) of EC patients is known to be relatively good, 10–15% of patients with low-risk EC experience a recurrence, while about 50% of patients with high-risk EC do not. For these reasons, there is a growing interest in a better understanding of genetic diversity, as well as a trend toward a more personalized diagnosis, surgical approach, adjuvant therapy, oncological surveillance, and the development of new and molecularly integrated protocols to manage endometrial cancer.

The Special Issue will focus on epidemiology, pathophysiology, diagnosis, molecular classification, and recent advancements in disease management.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)